Common use of Collaboration Costs Clause in Contracts

Collaboration Costs. 2.3.1. Novartis and Akcea will [***] the costs associated with the [***] and [***] under the Pre-Option Development Plan, which [***] Akcea estimates will cost US$[***] for [***]. Novartis will pay Akcea US$[***] for such [***] and [***] as follows: (i) US$[***] payment upon [***] for the [***] * ***Confidential Treatment Requested and [***] (expected in [***] but no earlier than the [***]); (ii) US$[***] payment upon the [***] in each of the [***] and [***] (expected in [***]); and (iii) US$[***] payment upon the later of (x) [***] and [***], and (y) [***], provided, in each case Novartis will pay the amounts under (i), (ii) and (iii) within [***] ([***]) calendar days from the date such invoice is received by Novartis (and Akcea will include with each such invoice [***] and [***]). In no event will [***] US$[***] for such [***] and [***]. 2.3.2. Except as otherwise expressly provided in this Agreement, Akcea will be responsible for all costs associated with the Akcea Activities under the Pre-Option Development Plan and the activities Akcea agrees to conduct under ARTICLE 1, and Novartis will be responsible for all costs associated with any Pre-Option Novartis Activities and the activities Novartis agreed to conduct under ARTICLE 1. 2.3.3. If a Regulatory Authority requires any changes to the Akcea Activities during the Option Period, then the Parties will discuss such changes in good faith through the CSC. If the CSC cannot mutually agree on whether to implement such a change to the Akcea Activities, then Akcea will have the final decision-making authority regarding [***] and each Party will only be responsible for paying the additional cost of such changes to the extent [***]. If Novartis requests any changes to the Akcea Activities that are not required by a Regulatory Authority and Akcea agrees (through the CSC) to implement such changes, then Novartis will pay Akcea for the additional cost in accordance with Section 7.10 and Akcea and Novartis will update APPENDIX 2 with any such revised activities.

Collaboration Costs. 2.3.1. Novartis and Akcea will [***] the costs associated with the [***] and [***] under the Pre-Option Development Plan, which [***] Akcea estimates will cost US$[***] for [***]. Novartis will pay Akcea US$[***] for such [***] and [***] as follows:: Confidential (i) US$[***] payment upon [***] for the [***] * ***Confidential Treatment Requested and [***] (expected in [***] but no earlier than the [***]); (ii) US$[***] payment upon the [***] in each of the [***] and [***] (expected in [***]); and (iii) US$[***] payment upon the later of (x) [***] and [***], and (y) [***], provided, in each case Novartis will pay the amounts under (i), (ii) and (iii) within [***] ([***]) calendar days from the date such invoice is received by Novartis (and Akcea will include with each such invoice [***] and [***]). In no event will [***] US$[***] for such [***] and [***]. 2.3.2. Except as otherwise expressly provided in this Agreement, Akcea will be responsible for all costs associated with the Akcea Activities under the Pre-Option Development Plan and the activities Akcea agrees to conduct under ARTICLE 1, and Novartis will be responsible for all costs associated with any Pre-Option Novartis Activities and the activities Novartis agreed to conduct under ARTICLE 1. 2.3.3. If a Regulatory Authority requires any changes to the Akcea Activities during the Option Period, then the Parties will discuss such changes in good faith through the CSC. If the CSC cannot mutually agree on whether to implement such a change to the Akcea Activities, then Akcea will have the final decision-making authority regarding [***] and each Party will only be responsible for paying the additional cost of such changes to the extent [***]. If Novartis requests any changes to the Akcea Activities that are not required by a Regulatory Authority and Akcea agrees (through the CSC) to implement such changes, then Novartis will pay Akcea for the additional cost in accordance with Section 7.10 and Akcea and Novartis will update APPENDIX Appendix 2 with any such revised activities.

Collaboration Costs. 2.3.1. Novartis and Akcea will [***] the costs associated with the [***] and [***] under the Pre-Option Development Plan, which [***] Akcea estimates will cost US$[***] for [***]. Novartis will pay Akcea US$[***] for such [***] and [***] as follows: (i) US$[***] payment upon [***] for the [***] * ***Confidential Treatment Requested 14 and [***] (expected in [***] but no earlier than the [***]); (ii) US$[***] payment upon the [***] in each of the [***] and [***] (expected in [***]); and (iii) US$[***] payment upon the later of (x) [***] and [***], and (y) [***], provided, in each case Novartis will pay the amounts under (i), (ii) and (iii) within [***] ([***]) calendar days from the date such invoice is received by Novartis (and Akcea will include with each such invoice [***] and [***]). In no event will [***] US$[***] for such [***] and [***]. 2.3.2. Except as otherwise expressly provided in this Agreement, Akcea Xxxxx will be responsible for all costs associated with the Akcea Activities under the Pre-Option Development Plan and the activities Akcea agrees to conduct under ARTICLE 1, and Novartis will be responsible for all costs associated with any Pre-Option Novartis Activities and the activities Novartis agreed to conduct under ARTICLE 1. 2.3.3. If a Regulatory Authority requires any changes to the Akcea Activities during the Option Period, then the Parties will discuss such changes in good faith through the CSC. If the CSC cannot mutually agree on whether to implement such a change to the Akcea Activities, then Akcea Xxxxx will have the final decision-making authority regarding [***] and each Party will only be responsible for paying the additional cost of such changes to the extent [***]. If Novartis requests any changes to the Akcea Activities that are not required by a Regulatory Authority and Akcea agrees (through the CSC) to implement such changes, then Novartis will pay Akcea for the additional cost in accordance with Section 7.10 and Akcea and Novartis will update APPENDIX 2 with any such revised activities.